帕博利珠单抗治疗晚期非小细胞肺癌(KEYNOTE-001):开放标签1期研究3年结果
KEYNOTE-001是一项多队列、开放标签1期研究,纳入550例晚期非小细胞肺癌患者(101例初治,449例经治),接受帕博利珠单抗治疗。
要点
- 初治患者3年客观缓解率41%,经治患者23%,缓解持久。
- PD-L1 TPS≥50%者中位总生存长于TPS 1-49%者。
- 3-5级治疗相关不良事件发生率12%,肺炎和疲劳最常见。
核心结论
- 帕博利珠单抗对表达PD-L1的晚期非小细胞肺癌初治和经治患者均提供持久缓解和长期总生存获益,安全性可耐受。
研究设计与样本
- 多队列、开放标签1期研究,纳入550例局部晚期或转移性非小细胞肺癌患者,其中101例初治、449例经治,接受帕博利珠单抗2 mg/kg每3周或10 mg/kg每2或3周治疗。
关键数值与推荐
- 3-5级治疗相关不良事件发生于66例(12%),30例(6%)因治疗相关不良事件停药。
- 最常见的3-4级治疗相关不良事件为肺炎(10例[2%])和疲劳(5例[1%])。
- 227例(41%)发生严重不良事件,其中50例(9%)为治疗相关。
临床怎么用
- 对于PD-L1表达的晚期非小细胞肺癌,帕博利珠单抗可作为初治或经治选择,尤其PD-L1 TPS≥50%者生存获益更明显。
- 治疗期间需监测肺炎和疲劳等不良事件,3-5级事件发生率12%,多数患者可耐受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The anti-programmed death 1 monoclonal antibody pembrolizumab has shown antitumour activity and is a first-line and second-line treatment option for patients with programmed death ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer. We report updated 3-year safety and efficacy outcomes from the phase 1 study, KEYNOTE-001. METHODS: KEYNOTE-001 is a multicohort, open-label, phase 1 study of pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in treatment naive or previously treated patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at baseline. Two cohorts were randomly assigned to a pembrolizumab dose by use of a computer-generated randomisation schedule at cohort-dependent ratios, and a further four cohorts were assigned to a pembrolizumab dose without randomisation. We present 3-year outcomes for the full analysis set of patients who received at least one dose of study treatment, pooled for all pembrolizumab doses. The primary efficacy endpoint was proportion of patients with objective response, analysed here as investigator-assessed response according to immune-related response criteria. Secondary efficacy endpoints included overall survival, duration of response, and progression-free survival. Safety endpoints included incidence of adverse events. This study is registered at ClinicalTrials.gov, number NCT01295827, and is ongoing. FINDINGS: Between May 8, 2012 and July 13, 2014, 550 patients (101 treatment naive and 449 previously treated) were enrolled. Median follow-up was 34·5 months at data cutoff (Sept 1, 2016). At 36 months, investigator-assessed objective response according to immune-related response criteria was achieved for 41 of 101 treatment naive patients (41% [95% CI 30·9-50·8]; median duration of response was 16·7 months [95% CI 12·6-not reached]) and 102 of 449 previously treated patients (23% [18·9-26·9]; 33·3 ([22·5-not reached]). The Kaplan-Meier estimate of overall survival at 36 months was 26·4% (95% CI 14·3-40·1) for treatment naive patients and 19·0% (15·0-23·4) for previously treated patients, with median overall survival of 22·3 months (95% CI 17·1-31·5) and 10·5 months (8·6-13·2). PD-L1 tumour proportion score ≥50% was associated with longer median overall survival (95% CI) versus tumour proportion score 1-49% (treatment naive: 34·9 [20·3-not reached] vs 19·5 [10·7-26·3] months; previously treated: 15·4 [10·5-18·5] vs 8·5 [6·0-12·7] months). Grade 3-5 treatment-related adverse events occurred in 66 patients (12%), and 30 (6%) discontinued owing to a treatment-related adverse event. The most frequent grade 3-4 treatment-related adverse events were pneumonitis (10 [2%] of 550) and fatigue (5 [1%] of 550). Overall, 227 patients (41%) of 550 had serious adverse events, of which 50 (9%) were treatment related. INTERPRETATION: Pembrolizumab provides durable response and long-term effects on overall survival, with tolerable safety, for treatment naive and previously treated patients with advanced non-small-cell lung cancer expressing PD-L1. FUNDING: Merck Sharp & Dohme Corp.
引用
- Leighl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med. 2019. PMID: 30876831. doi:10.1016/S2213-2600(18)30500-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。